120
Participants
Start Date
January 18, 2024
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2025
HS-20093
Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
RECRUITING
Fudan University Cancer Hospital, Shanghai
RECRUITING
Peking University Cancer Hospital, Beijing
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Xiangya Hospital Central South University, Changsha
RECRUITING
West China hospital, sichuan university, Chengdu
RECRUITING
The First Affiliate Hospital of GUANGZHOU Medical University, Guangzhou
RECRUITING
Yunnan Cancer Hospital, Kunming
RECRUITING
Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
RECRUITING
Liaoning Tumor Hospital, Shengyang
RECRUITING
Shengjing Hospital of China Medical University, Shengyang
RECRUITING
The First Hospital of China Medical University, Shengyang
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Tongji Hospital, Wuhan
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Hansoh BioMedical R&D Company
INDUSTRY